The Cardiff medtech firm secured the capital from existing shareholders including the Development Bank of Wales and Wealth Club members.
"This has been another important year of growth and development for Bond Digital Health. Now that we have several international customers signed up to our platform, we need to make sure we successfully service their needs 24/7. This funding will help us do that by ensuring we have the right people in the right roles. I’d like to put on record my thanks to the Development Bank of Wales and Wealth Club for helping us get to this point."
The financing round was co-led by Boehringer Ingelheim Venture Fund and Parkwalk Advisors, with participation from Tencent and Oxford University Innovation Fund.
"Over the past decade Brainomix has created the market for stroke AI imaging. As a spin-out from the University of Oxford it is an example of the UK's world-leading strengths in life sciences and AI-enabled medtech, combining expertise in clinical care and software development with more than 150 years' experience in the field across its leadership team."
The Oxford Science Enterprises-led round will support US expansion and continued domestic growth in healthcare.
"I’m delighted our investors have again demonstrated their belief in the vast potential that Navenio can bring by ensuring ‘right person, right place, right time’. Artificial intelligence is one of many technologies making a real-world impact in the health sector, and this investment enables the company to rapidly spearhead international digital transformation."
The oversubscribed raise was led by investment platform Wealth Club alongside existing backers Deepbridge Capital and Boundary Capital.
"Glyconics offers a transformational, cost-efficient, rapid and non-invasive approach to diabetes screening – and it is testament to this pioneering device and all at Team Glyconics that this raise was so significantly over-subscribed. We are delighted to be continuing with our existing investors and, of course, welcome our new investors from Wealth Club and other private investors to the fold."
The seed round was co-led by Oxford Capital and YZR to fund expansion into international markets.
"Increasing access to the right diagnostic imaging and testing is vital to saving lives. It offers preventive healthcare that, if delayed, can cause significant problems to the patient and put even greater pressure on the healthcare system. In my role as an osteopath I've seen how the deterioration of patient wellbeing can be impacted by the cost and access of such tests. With this new investment we can continue to grow our network to get the tests that help to direct patients to the optimal therapy for the best outcome."
— Jasper Nissim, Co-Founder and UK Managing Director
